2,977 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Bryce Point Capital LLC

Bryce Point Capital LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 2,977 shares of the company’s stock, valued at approximately $485,000.

A number of other large investors have also added to or reduced their stakes in the company. Howard Capital Management Group LLC raised its position in Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after purchasing an additional 883 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Zoetis by 17.3% in the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after acquiring an additional 351,372 shares during the period. Integrated Wealth Concepts LLC lifted its stake in Zoetis by 1.3% in the third quarter. Integrated Wealth Concepts LLC now owns 7,271 shares of the company’s stock worth $1,421,000 after acquiring an additional 92 shares during the period. Resurgent Financial Advisors LLC purchased a new position in Zoetis during the 3rd quarter valued at $211,000. Finally, Royal London Asset Management Ltd. raised its holdings in Zoetis by 4.8% in the 3rd quarter. Royal London Asset Management Ltd. now owns 212,693 shares of the company’s stock worth $41,556,000 after purchasing an additional 9,746 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Stock Down 4.9 %

Shares of Zoetis stock opened at $151.76 on Friday. The company has a 50-day simple moving average of $165.71 and a two-hundred day simple moving average of $173.58. The stock has a market capitalization of $67.96 billion, a PE ratio of 27.74, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.32%. Zoetis’s payout ratio is 36.56%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.